CorMedix (NASDAQ:CRMD) Trading Down 6% - Should You Sell?
CorMedix (NASDAQ:CRMD) Stock Price Down 6% - Time to Sell...
MarketBeat·3d ago
More News
SNY & REGN's Dupixent Gets EU Nod for Chronic Spontaneous Urticaria
Sanofi/Regeneron's Dupixent wins EU nod for chronic spontaneous urticaria, marking its seventh approved indication across inflammatory diseases in the EU.
Zacks·4d ago
BAYRYs Cardiovascular Drug Hits Goals in Late-Stage Study
Bayer's asundexian hits key goals in the OCEANIC-STROKE study, showing reduced ischemic stroke risk without added major bleeding.
Zacks·5d ago
FDA Approves MRK's Keytruda & Keytruda SC Combo in Bladder Cancer
Merck gains FDA nod for Keytruda and Keytruda Qlex with Padcev in MIBC, marking the first PD-1 inhibitor plus ADC regimens for this patient group.
Zacks·5d ago
AGIO Stock Hits 52-Week Low on Mixed Sickle Cell Disease Study Results
Agios slides to a 52-week low after mixed phase III RISE UP data show a hemoglobin boost but no significant cut in pain crises.
Zacks·9d ago
ALKS Raises Its Offer to Buy Avadel In Response to Lundbeck's Proposal
Alkermes lifts its bid to buy Avadel for $22.50 per share as its takeover fight with Lundbeck intensifies and shifts the deal's momentum.
Zacks·9d ago
CorMedix (NASDAQ:CRMD) Trading Up 2.6% - Time to Buy?
CorMedix (NASDAQ:CRMD) Stock Price Up 2.6% - Here's Why...
MarketBeat·10d ago
Insmed Stock Rise on EU Nod for Lung Disease Drug, Brinsupri
INSM climbs after the EU clears Brinsupri as the first approved treatment for NCFB, backed by phase III ASPEN and phase II WILLOW results.
Zacks·10d ago
CorMedix (NASDAQ:CRMD) Trading Down 9.2% - Here's Why
CorMedix (NASDAQ:CRMD) Shares Down 9.2% - Here's What Happened...
MarketBeat·11d ago
JAZZ Hits 52-Week High on Encouraging Gastric Cancer Study Data
Jazz jumps to a 52-week high after HERIZON-GEA-01 shows Ziihera combos delivering meaningful PFS and OS gains in HER2+ GEA.